Park Square Financial Group’s PharmaCyte Biotech PMCB Stock Holding History

Park Square Financial Group’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37	Closed	-$40	–	768
2025 Q2	$40	Hold	37	–	–	﹤0.01%	1001
2025 Q1	$46	Hold	37	–	–	﹤0.01%	957
2024 Q4	$58	Buy	+37	New	+$64	﹤0.01%	948

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Park Square Financial Group's PMCB Position: Q3 2025 in Review

Park Square Financial Group sold out of PharmaCyte Biotech (PMCB) in Q3 2025, closing a stake of 37 shares — an estimated $40 sold.

Park Square Financial Group first reported a position in PMCB in Q4 2024 and held it in 3 quarters. The position peaked at $58 in Q4 2024. 23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

Park Square Financial Group reported no remaining PharmaCyte Biotech position as of Q3 2025 after selling out during the quarter.
Park Square Financial Group sold 37 PharmaCyte Biotech shares in Q3 2025, an estimated $40.
Park Square Financial Group first reported a position in PharmaCyte Biotech in Q4 2024 and held it in 3 quarters.
Park Square Financial Group's PharmaCyte Biotech position peaked at $58 in Q4 2024.
23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.